Takuya Toyonaga1, Kenji Hirata1, Shigeru Yamaguchi2,3, Kanako C Hatanaka4, Sayaka Yuzawa5, Osamu Manabe1, Kentaro Kobayashi1, Shiro Watanabe1, Tohru Shiga1, Shunsuke Terasaka6, Hiroyuki Kobayashi6, Yuji Kuge7, Nagara Tamaki1. 1. Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan. 2. Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan. yama-shu@med.hokudai.ac.jp. 3. Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. yama-shu@med.hokudai.ac.jp. 4. Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan. 5. Department of Cancer Pathology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 6. Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 7. Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan.
Abstract
PURPOSE: Tumor necrosis is one of the indicators of tumor aggressiveness. (18)F-fluoromisonidazole (FMISO) is the most widely used positron emission tomography (PET) tracer to evaluate severe hypoxia in vivo. Because severe hypoxia causes necrosis, we hypothesized that intratumoral necrosis can be detected by FMISO PET in brain tumors regardless of their histopathology. We applied FMISO PET to various types of brain tumors before tumor resection and evaluated the correlation between histopathological necrosis and FMISO uptake. METHODS: This study included 59 brain tumor patients who underwent FMISO PET/computed tomography before any treatments. According to the pathological diagnosis, the brain tumors were divided into three groups: astrocytomas (group 1), neuroepithelial tumors except for astrocytomas (group 2), and others (group 3). Two experienced neuropathologists evaluated the presence of necrosis in consensus. FMISO uptake in the tumor was evaluated visually and semi-quantitatively using the tumor-to-normal cerebellum ratio (TNR). RESULTS: In visual analyses, 26/27 cases in the FMISO-positive group presented with necrosis, whereas 28/32 cases in the FMISO-negative group did not show necrosis. Mean TNRs with and without necrosis were 3.49 ± 0.97 and 1.43 ± 0.42 (p < 0.00001) in group 1, 2.91 ± 0.83 and 1.44 ± 0.20 (p < 0.005) in group 2, and 2.63 ± 1.16 and 1.35 ± 0.23 (p < 0.05) in group 3, respectively. Using a cut-off value of TNR = 1.67, which was calculated by normal reference regions of interest, we could predict necrosis with sensitivity, specificity, and accuracy of 96.7, 93.1, and 94.9 %, respectively. CONCLUSIONS: FMISO uptake within the lesion indicated the presence of histological micro-necrosis. When we used a TNR of 1.67 as the cut-off value, intratumoral micro-necrosis was sufficiently predictable. Because the presence of necrosis implies a poor prognosis, our results suggest that FMISO PET could provide important information for treatment decisions or surgical strategies of any type of brain tumor.
PURPOSE:Tumornecrosis is one of the indicators of tumor aggressiveness. (18)F-fluoromisonidazole (FMISO) is the most widely used positron emission tomography (PET) tracer to evaluate severe hypoxia in vivo. Because severe hypoxia causes necrosis, we hypothesized that intratumoral necrosis can be detected by FMISO PET in brain tumors regardless of their histopathology. We applied FMISO PET to various types of brain tumors before tumor resection and evaluated the correlation between histopathological necrosis and FMISO uptake. METHODS: This study included 59 brain tumorpatients who underwent FMISO PET/computed tomography before any treatments. According to the pathological diagnosis, the brain tumors were divided into three groups: astrocytomas (group 1), neuroepithelial tumors except for astrocytomas (group 2), and others (group 3). Two experienced neuropathologists evaluated the presence of necrosis in consensus. FMISO uptake in the tumor was evaluated visually and semi-quantitatively using the tumor-to-normal cerebellum ratio (TNR). RESULTS: In visual analyses, 26/27 cases in the FMISO-positive group presented with necrosis, whereas 28/32 cases in the FMISO-negative group did not show necrosis. Mean TNRs with and without necrosis were 3.49 ± 0.97 and 1.43 ± 0.42 (p < 0.00001) in group 1, 2.91 ± 0.83 and 1.44 ± 0.20 (p < 0.005) in group 2, and 2.63 ± 1.16 and 1.35 ± 0.23 (p < 0.05) in group 3, respectively. Using a cut-off value of TNR = 1.67, which was calculated by normal reference regions of interest, we could predict necrosis with sensitivity, specificity, and accuracy of 96.7, 93.1, and 94.9 %, respectively. CONCLUSIONS:FMISO uptake within the lesion indicated the presence of histological micro-necrosis. When we used a TNR of 1.67 as the cut-off value, intratumoral micro-necrosis was sufficiently predictable. Because the presence of necrosis implies a poor prognosis, our results suggest that FMISO PET could provide important information for treatment decisions or surgical strategies of any type of brain tumor.
Authors: Kristin R Swanson; Gargi Chakraborty; Christina H Wang; Russell Rockne; Hana L P Harpold; Mark Muzi; Tom C H Adamsen; Kenneth A Krohn; Alexander M Spence Journal: J Nucl Med Date: 2008-12-17 Impact factor: 10.057
Authors: Mindy D Szeto; Gargi Chakraborty; Jennifer Hadley; Russ Rockne; Mark Muzi; Ellsworth C Alvord; Kenneth A Krohn; Alexander M Spence; Kristin R Swanson Journal: Cancer Res Date: 2009-04-14 Impact factor: 12.701
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Ramon F Barajas; Kenneth A Krohn; Jeanne M Link; Randall A Hawkins; Jennifer L Clarke; Miguel H Pampaloni; Soonmee Cha Journal: Biomedicines Date: 2016-10-31
Authors: Shiliang Huang; Joel E Michalek; David A Reardon; Patrick Y Wen; John R Floyd; Peter T Fox; Geoffrey D Clarke; Paul A Jerabek; Kathleen M Schmainda; Mark Muzi; Hyewon Hyun; Eudocia Quant Lee; Andrew J Brenner Journal: Sci Rep Date: 2021-04-07 Impact factor: 4.379